戻る
Avidity Biosciences Inc (RNA)価格
RNA 株価推移チャート
RNA 収入
Avidity Biosciences Inc
$72.9
0.1%
$0.08
終値： Feb 06, 16:00:00 GMT-5
$72.9
0%
$0
アフターマーケット：Feb 06, 20:00:00 GMT-5
最新の利益結果: Q3 '25
報告済み: 2025-11-10
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
RNAの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Avidity Biosciences Inc RNAの前四半期の収益はどうでしたか？
Avidity Biosciences Incの収益見積もりはいくらですか？
Avidity Biosciences Incの収益品質スコアはどれくらいですか？
Avidity Biosciences Incはいつ収益を報告しますか？
Avidity Biosciences Incの予想収益はいくらですか？
Avidity Biosciences Incは収益予想を上回りましたか？
主要データ
前終値
$72.82
始値
$72.92
当日レンジ
$72.78 - $72.95
52週レンジ
$21.51 - $73.06
取引高
2.0M
平均取引高
2.2M
1株当たり利益(TTM)
-4.17
配当利回り
--
時価総額
$10.9B
RNAとは何ですか？
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). The company is headquartered in San Diego, California and currently employs 391 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.